ChemoCentryx Inc. (NASDAQ:CCXI) traded down 0.4% during trading on Friday . The company traded as low as $4.75 and last traded at $4.80, with a volume of 79,560 shares trading hands. The stock had previously closed at $4.82.

A number of equities research analysts recently commented on the company. Cowen and Company reissued a “hold” rating on shares of ChemoCentryx in a research report on Thursday, May 19th. Zacks Investment Research lowered ChemoCentryx from a “buy” rating to a “hold” rating in a research report on Monday, May 16th.

The firm’s 50-day moving average price is $4.83 and its 200 day moving average price is $3.98. The stock’s market cap is $212.59 million.

ChemoCentryx (NASDAQ:CCXI) last released its quarterly earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.27) by $0.07. Equities analysts anticipate that ChemoCentryx Inc. will post ($0.35) earnings per share for the current year.

In other ChemoCentryx news, Director Geoffrey M. Parker acquired 40,000 shares of the company’s stock in a transaction dated Friday, May 13th. The stock was purchased at an average price of $4.03 per share, with a total value of $161,200.00. Following the completion of the purchase, the director now directly owns 13,514 shares in the company, valued at approximately $54,461.42. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Thomas A. Edwards acquired 25,000 shares of the company’s stock in a transaction dated Monday, May 16th. The stock was acquired at an average cost of $4.05 per share, with a total value of $101,250.00. Following the purchase, the director now owns 41,977 shares of the company’s stock, valued at $170,006.85. The disclosure for this purchase can be found here.

ChemoCentryx, Inc (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.